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The actin cytoskeleton is believed to contribute to the formation of clathrin-coated pits, although the specific
components that connect actin filaments with the endocytic machinery are unclear. Cortactin is an F-actinassociated protein, localizes within membrane ruffles in cultured cells, and is a direct binding partner of the
large GTPase dynamin. This direct interaction with a component of the endocytic machinery suggests that
cortactin may participate in one or several endocytic processes. Therefore, the goal of this study was to test
whether cortactin associates with clathrin-coated pits and participates in receptor-mediated endocytosis.
Morphological experiments with either anti-cortactin antibodies or expressed red fluorescence protein-tagged
cortactin revealed a striking colocalization of cortactin and clathrin puncta at the ventral plasma membrane.
Consistent with these observations, cells microinjected with these antibodies exhibited a marked decrease in
the uptake of labeled transferrin and low-density lipoprotein while internalization of the fluid marker dextran
was unchanged. Cells expressing the cortactin Src homology three domain also exhibited markedly reduced
endocytosis. These findings suggest that cortactin is an important component of the receptor-mediated endocytic machinery, where, together with actin and dynamin, it regulates the scission of clathrin pits from the
plasma membrane. Thus, cortactin provides a direct link between the dynamic actin cytoskeleton and the
membrane pinchase dynamin that supports vesicle formation during receptor-mediated endocytosis.
region that, through the three-amino-acid DDW motif, binds
to the Arp2/3 complex, where it appears to regulate actin
polymerization (36, 39, 40). Cortactin also contains tandem
repeats that form F-actin-binding domains (41, 43) and an
␣-helical proline-rich region that includes tyrosine residues
that are phosphorylated by c-Src (12, 13). These unique features make it likely that cortactin participates in numerous
actin-dependent cytoskeletal processes. For example, the observations that cortactin is localized to cortical ruffles and that
cells expressing high levels of cortactin have enhanced cell
motility suggests that cortactin functions together with actin to
promote cell motility (23, 43). However, recent studies have
reported that cortactin associates with motile endosomes and
have implicated this protein in actin nucleation as it may relate
to vesicle transport, targeting, or fusion (14, 16, 22, 29). A
recent study reporting a direct binding of Dyn2 and cortactin
was one of the first to demonstrate a physical interaction between an actin-binding protein and a component of the endocytic machinery (19). Whether cortactin participates in endocytosis is currently undefined.
In this study we tested whether cortactin functions during
the initial stages of receptor-mediated endocytosis (RME).
Specifically, we asked whether cortactin, normally found at the
cell cortex, might also associate with CCPs. Dyn2 mutants that
alter RME were used to gain insight into the function and
targeting of cortactin to CCPs. The role of cortactin in endocytosis was tested directly through microinjection of affinitypurified antibodies to distinct domains of cortactin, including
the dynamin-binding SH3 domain, and by transient expression
of the SH3 domain. Multiple endocytic pathways were tested,
including the RME uptake of ligands including fluorescently

The actin cytoskeleton, with its associated proteins, has been
implicated in endocytic processes in both yeast and mammalian cells (5, 25, 41). How this cytoskeletal network might
interact with the endocytic machinery to regulate vesicle formation and scission remains unclear. Recently, Pelkmans and
colleagues reported that actin and dynamin accumulated at
simian virus 40-docked caveolae concomitant with internalization, thus demonstrating that actin functions during the endocytic process (24). Similarly, Merrifield et al. demonstrated
that clathrin, dynamin, and actin are sequentially recruited to
form clathrin pits, marked by an accumulation of actin and
movement of the vesicles away from the plasma membrane
(20). Both of these studies demonstrated an accumulation of
dynamin and actin at the forming endocytic membranes but
did not directly link the endocytic and cytoskeletal machineries. Recently, it was demonstrated that the actin-binding protein cortactin associates directly with the large GTPase dynamin (Dyn2) via their Src homology three (SH3) and prolinerich domains (PRD), respectively (19). As Dyn2 participates in
the liberation of clathrin-coated pits (CCPs) from the plasma
membrane, a potential link exists between the endocytic machinery and the actin cytoskeleton through cortactin (18).
Cortactin is an 80- and 85-kDa protein that localizes within
membrane ruffles in cultured cells (19, 43) and was originally
identified as a substrate for the protein tyrosine kinase pp60Src
(21, 44). Importantly, cortactin contains an N-terminal acidic
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MATERIALS AND METHODS
Antibodies, ligands, and stains. An anticlathrin monoclonal antibody (X-22)
was from the American Type Culture Collection, Rockville, Md. The anti-kinesin
(MC44) antibody was raised against a peptide sequence representing amino acids
QKKLSGKLYLVDLAGSEKVSKTGAEGT. The anti-cortactin AB3 antibody
was raised against the peptide DKSAVGFDYQGKTEKHESQKDYSK, present
in the third F-actin-binding domain, and the anti-cortactin C-Tyr antibody was
raised against the peptide HYQAEDDTYDGYESDLGIT, present in the Cterminal region of cortactin. The anti-cortactin SH3 antibody was raised against
the peptide YDYQAAGDDEISFDPDDVITNIEM, present in the SH3 domain
of cortactin. The cortactin antibodies are specific, as confirmed by immunoblotting and immunofluorescence analysis compared to a commercially available
monoclonal cortactin antibody 4F11 (Upstate Biotechnology, Lake Placid, N.Y.).
Goat anti-rabbit or goat anti-mouse secondary antibodies conjugated to Alexa
488 or 594 were from Molecular Probes (Eugene, Oreg.). Transferrin Alexa 488
or 594, DiI-LDL, and rhodamine- or FITC-dextran (3,000 molecular weight) for
immunocytochemical staining were from Molecular Probes. All other chemicals
and reagents, unless otherwise stated, were from Sigma (St. Louis, Mo.).
Dynamin and cortactin cDNAs. The Dyn2 (aa) K44A-GFP and Dyn2 (amino
acid) ⌬PRD-GFP plasmids were as described previously (3, 19). Oligonucleotide
primers specific for cortactin were designed (MacVector or Oligo, version 6.51)
and synthesized (Applied Biosystems model 394 DNA/RNA synthesizer) by
using the cortactin cDNA sequence from GenBank (accession no. AF054619).
Primers designed for cortactin are Cort 5⬘ (ATGTGGAAAGCCTCTGCAGG
CCATGCTGTG) and Cort 3⬘, (CTACTGCCGCAGC TCCACATAG). Fulllength cDNAs were amplified by using the XL PCR kit (Perkin Elmer, Branchburg, N.J.). The PCR cycle conditions were 94°C for 1 min and 62°C for 5 min
for 28 cycles followed by 72°C for 7 min. The cortactin SH3 domain was amplified
by using a PCR kit (Invitrogen, Carlsbad, Calif.). Primers designed for the
cortactin SH3 domain were SH3-5⬘ (ATGTATGACTACCAGGCTGCTGGCG
ATG) and the 3⬘ primer Cort 3⬘. The cortactin full-length DNA template was
used in the PCR; cycle conditions were as described above for 30 cycles. The
PCR fragments were ligated into the eukaryotic expression vector pCR3.1 (Invitrogen). For subcloning, positive pCR3.1 subclones were subjected to PCR with
5⬘ and 3⬘ PCR primers for cortactin that introduced novel restriction enzyme
sites (EcoRI and BamHI). Amplification products containing the EcoRI and
BamHI restriction sites were digested and subcloned into the pDsRed-N1 (RFP)
expression vector (Clontech, Palo Alto, Calif.). Restriction enzymes were from
Promega (Madison, Wis.) and Life Technologies, Inc. (Invitrogen).
Cell culture and transfection. Clone 9 cells, an epithelial cell line isolated from
normal rat liver (ATCC CRL-1439), were maintained in Ham’s F-12K medium
supplemented with 10% fetal bovine serum (Invitrogen), 100 U of penicillin/ml,
and 100 g of streptomycin/ml in 5% CO2–95% air at 37°C. Cells were cultured
in T-75 flasks (Fisher Scientific, Pittsburgh, Pa.) or on 22- by 22-mm glass
coverslips for transfections and immunocytochemistry, respectively. Transfections were performed with the Lipofectamine Plus reagent kit (Invitrogen).
Immunofluorescence and confocal microscopy. For immunofluorescence microscopy and confocal microscopy, cells were grown on coverslips for 1 to 2 days
and prepared as described previously (2). Clone 9 cells were double stained with
anti-cortactin (AB3) polyclonal antibody or anti-cortactin (C-Tyr) polyclonal
antibody with clathrin (X-22) monoclonal antibody. Transiently transfected cortactin-RFP-expressing cells were also costained with clathrin (X-22). The anticortactin and anti-SH3 antibodies were used to identify the Cort SH3-pCR3.1-

expressing cells. For the transferrin uptake experiments, the cells were
permeabilized with 0.01% digitonin (Fluka, Ronkonkoma, N.Y.). Cells were
viewed with an Axiovert 35 epifluorescence microscope (Carl Zeiss, Inc., Thornwood, N.Y.) equipped with a 100-W mercury lamp and a 100⫻ objective lens
(Zeiss Plan-Neofluar 1.30) and a confocal microscope (LSM-310 or 510; Carl
Zeiss, Inc.) equipped with an argon–krypton laser and a 100⫻ objective lens.
Electron microscopy. Electron microscopy of replica coated, unroofed COS7
cells and labeling with anti-cortactin antibodies were performed as described
previously by J. Heuser (9, 10).
Microinjection of anti-cortactin and kinesin antibodies and endocytic assays.
Clone 9 cells were microinjected with either buffer alone (10 mM KH2PO4 [pH
7.2] and 75 mM KCl) or buffer containing cortactin (AB3, 6.2 mg/ml), cortactin
(C-Tyr, 9.4 mg/ml), or anti-kinesin (7.2 mg/ml) antibodies, respectively. Fixable
rhodamine- or FITC-dextrans were included in the injectate to identify the
injected cells. The cells recovered in 5% CO2–95% air at 37°C for 4 to 6 h prior
to the endocytic assays (8).
Quantitation of transferrin, LDL, and dextran uptake in microinjected cells.
Images for quantitation were acquired by using a cooled charge-coupled device
camera (Photometrics SenSys, Tuscon, Ariz.) driven by Metamorph (Universal
Imaging, West Chester, Pa.). All images of microinjected cells were taken at full
resolution (1,024 by 1,024 pixels) with the same acquisition settings (exposure
time, 5 s; 12-bit grayscale). The percentage of cells demonstrating an inhibition
of transferrin or dextran uptake was determined by visual inspection. The mean
percentage of cells showing reduced internalization was determined from three
separate experiments and at least 150 cells for each condition. Fluorescence
intensity quantitation was performed with IPLab (Scanalytics, Inc., Fairfax, Va.).
The area occupied by each cell was traced, and the mean fluorescence intensity
per unit area was determined for at least 100 cells in each injection condition.

RESULTS
Cortactin localizes to CCPs in cultured cells. As novel cortactin antibodies were generated for this study, we first needed
to demonstrate their specificity. Polyclonal antibodies against
cortactin peptides were raised to distinct epitopes in cortactin,
the third actin-binding motif (AB3) near the center of the
protein, and a C-terminal region adjacent to the SH3 domain
known to contain several Src-phosphorylated tyrosines (C-Tyr)
(Fig. 1a) (12, 13). After purification and concentration, these
antibodies were characterized by using multiple criteria and
their specificities were compared to a commercially available
cortactin monoclonal antibody (see Materials and Methods).
First, immunoblotting of liver homogenate, cultured rat hepatocyte (clone 9) lysate, and purified His6-cortactin protein
demonstrated that all three antibodies specifically detected the
characteristic cortactin doublet at 80 and 85 kDa (Fig. 1b).
Next, we used these three antibodies to immunoprecipitate
cortactin from clone 9 lysate. Immunoblotting of the respective
immunoprecipitations with the monoclonal antibody revealed
that a substantial amount of cortactin was isolated (Fig. 1c).
Importantly, when these immunoprecipitations were subjected
to Coomassie blue staining (silver staining was also performed)
(data not shown), cortactin represented the overwhelming majority of the protein present (Fig. 1d). These experiments demonstrated that the three distinct antibody reagents used in this
study are specific for cortactin.
To define the localization and function of cortactin in cultured clone cells, the purified cortactin antibodies were used
for indirect immunofluorescence staining (Fig. 2a and b). Both
antibodies gave nearly identical staining patterns, stained the
cell cortex, as reported previously (19, 40, 43), and also labeled
prominent, punctate foci along the cell surface. Costaining of
these cells with monoclonal antibodies to the clathrin heavy
chain, or Dyn2 (data not shown), demonstrated a striking, but
not absolute, colocalization of these proteins at plasma mem-
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tagged transferrin and low-density lipoprotein (LDL) or fluid
(rhodamine or fluorescein isothiocyanate [FITC]-tagged dextran) by cultured epithelial cells. A striking colocalization of
cortactin was observed with both clathrin and Dyn2 puncta on
the cell surface by using two distinct cortactin antibodies and
red fluorescence protein-tagged cortactin (cortactin-RFP).
Further, when RME and clathrin organization was disrupted
through the expression of Dyn2 mutant proteins, cortactin
redistributed to localize with clathrin in large surface plaques.
In support of these findings, microinjection of the same antibodies used for colocalization and expression of the cortactin
SH3 domain resulted in a substantial inhibition of clathrinmediated transferrin and LDL uptake while fluid uptake remained unaffected. These findings demonstrate a role for cortactin at the site of endocytic pit formation and scission.
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brane puncta (Fig. 2a to b⬙). To further confirm these antibody
localization results, clone 9 cells expressing a cortactin-RFP
fusion protein (Cort-B-pDsRed-N1) were fixed and stained
with antibodies to clathrin (Fig. 2c to c⬙) or Dyn2 (data not
shown). As for the antibody-stained cells, the expressed cortactin-RFP localized to the cell cortices and in small puncta
along the cell surface that stained positive for both clathrin and
Dyn2. A majority, but not all, of the tagged cortactin protein
associated with clathrin foci (Fig. 2c⬙).
To visualize cortactin’s localization at the ultrastructural
level and gain insight into its potential function at CCPs, unroofed preparations of cultured COS7 cells were processed for
immuno-gold electron microscopy with the AB3 or C-Tyr cortactin antibodies by using the methods of Heuser (9, 10). This
preparation allows high-resolution imaging of immuno-gold
complexes while maintaining remarkable morphological preservation of coat and cytoskeletal components along the cell
cortex at the plasma membrane. In support of the fluorescence
microscopy images shown in Fig. 2a to c⬙, the immuno-gold
electron microscopy wtih cortactin antibodies revealed a strong
labeling of both flat and highly curved clathrin lattices (Fig. 2d
to f). Interestingly, gold particles appeared to be distributed
randomly over the surface of flat clathrin lattices, but this

distribution became restricted to a ring around the base of the
clathrin coat as the pit invaginated (Fig. 2d versus e and f). This
circular distribution along the base of protruding pits closely
resembled that of Dyn2 as viewed in the same preparation
(data not shown). Importantly, the cortactin antibodies also
labeled actin filaments in these preparations (Fig. 2d to e).
Thus, two different purified antibodies directed to distinct motifs in the cortactin protein, as well as cortactin-RFP, showed
significant localization, with CCPs at both the light and ultrastructural levels. These morphological findings strongly supported a potential role for cortactin in RME together with
actin and dynamin.
To further confirm that cortactin is a component of CCPs
and to elucidate the role of cortactin together with Dyn2 at
CCPs, we disrupted the normal punctate distribution of clathrin in cultured cells via expression of mutant Dyn2 proteins.
The GTP-binding and hydrolysis-deficient Dyn2K44A is often
used to block RME, and its expression is proposed to block pits
at the intermediate stage of internalization, prior to final constriction of the vesicle neck (4, 11, 37). Dynamin that lacks the
PRD, Dyn2⌬PRD, has a diffuse, largely cytoplasmic staining
pattern, cannot bind to cortactin (19), and was recently shown
not to target to CCPs, resulting in blocked RME (32).
Dyn2⌬PRD is proposed to exert its dominant-negative effect
by inappropriately targeting in cells and through oligomerization with endogenous dynamin (19, 32). Interestingly, when
Dyn2K44A- or Dyn2⌬PRD-expressing cells (data not shown)
were stained for cortactin and clathrin, the distribution of
plasma membrane cortactin changed to become part of the
large, abnormal clathrin aggregates (Fig. 3). The fact that cortactin localization changed along with CCP formation and distribution supports the morphological observations shown in
Fig. 2, indicating that the actin-binding protein cortactin is part
of the clathrin endocytic machinery.
Cortactin, including its SH3 domain, is important for efficient RME. To directly test the role of cortactin in endocytosis,
the same affinity-purified antibodies used to show a localization of cortactin to CCPs (Fig. 2) were microinjected into clone
9 cells. First, we demonstrated that the injected cells did not
display any gross morphological defects compared to noninjected, buffer-injected, or kinesin antibody-injected cells (Fig. 4
and data not shown). This suggested that the cells were healthy
in the context of these experiments. Based on cortactin’s localization to CCPs, we expected that an antibody-mediated
inhibition of cortactin function could have profound effects on
RME. To test if the cortactin antibodies that colocalize with
CCPs might affect clathrin-mediated endocytosis of transferrin
or LDL or fluid-phase endocytosis of dextran, cells were injected with control solutions (microinjection buffer alone or a
kinesin antibody) or affinity-purified cortactin antibodies. Injected cells recovered for 4 h prior to incubation with fluorescent ligands. Subsequent to rinsing and fixation, cells were
scored in a blind fashion as normal or significantly inhibited for
endocytosis. While buffer alone (data not shown) or the purified kinesin antibody had no effect on transferrin uptake (Fig.
4a), both the cortactin AB3 and C-Tyr antibodies exhibited a
profound inhibitory effect on ligand uptake (Fig. 4b and c). In
over 80% (AB3-injected) and 70% (C-Tyr-injected) of the cells
counted, transferrin internalization appeared completely ablated (Fig. 4e). Interestingly, while transferrin staining in con-

Downloaded from http://mcb.asm.org/ on January 6, 2014 by Washington University in St. Louis

FIG. 1. Polyclonal antibodies raised against distinct cortactin peptides appear specific for the cortactin protein. (a) The diagram depicts
different domains of the cortactin protein including the F-actin-binding
sites, C-terminal tyrosines that are phosphorylated by Src kinases, and
the SH3 domain that binds Dyn2. Areas that peptide antibodies were
directed against are indicated (asterisks). To test the specificity of the
antibodies, peptide affinity-purified serum was used for immunoblotting and immunoprecipitation. (b) An equal mass of total lysate from
rat liver homogenate, cultured hepatocyte (clone 9 [C9]) lysate, or
purified His6-cortactin (Cort) were immunoblotted with either the
AB3, C-Tyr (C-Y), or a commercially available cortactin monoclonal
antibody (4F11 [F11]; Upstate Biotechnology). The polyclonal anticortactin antibodies and the 4F11 antibody specifically detected cortactin in all conditions. (c) Cortactin was immunoprecipitated (IP)
from clone 9 lysates with each antibody, and the precipitated protein
was immunoblotted with the 4F11 antibody. All cortactin antibodies
tested precipitated cortactin that was easily detected by immunoblotting. (d) Coomassie staining of the immunoprecipitation reactions
demonstrated that a substantial amount of cortactin was obtained and
that it was the major protein species present (compare the bands from
the immunoprecipitations against 0.2 g of purified His6-cortactin
[Cort]). IgG, immunoglobulin G.
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FIG. 2. Cortactin antibodies stain numerous plasma membrane foci that colocalize with CCPs. (a to c⬙) Immunofluorescence microscopy of
cultured clone 9 cells stained with cortactin antibodies directed to the C-Tyr (a) and the actin-binding (AB3) (b) domains. Both antibodies labeled
small punctate foci on the basal plasma membrane that colocalize significantly (arrows) with clathrin (a⬙ and b⬙). Fluorescence images of clone 9
cells expressing cortactin-RFP and costained for clathrin are shown (c to c⬙). As for the antibody staining, significant levels of the tagged cortactin
protein associated with numerous punctate foci along the ventral membrane. (c⬙) Higher-magnification images of the boxed regions show that a
substantial number of the cortactin-RFP- and clathrin-positive puncta overlap or are in close association. (d to f) Immunoelectron microscopy of
the inner plasma membrane of unroofed COS7 cells labeled with the C-Tyr (d and e) and AB3 (f) cortactin antibodies. Flat or curved clathrin
lattices as well as actin filaments can be seen associated with the plasma membrane. Numerous immuno-gold particles (yellow) can be seen
specifically labeling the clathrin cage and appear to cluster in a concentric ring along the pit base, as opposed to the bulb, as the membrane
invaginates (g). (d to f) Gold particles can also be resolved on actin filaments and actin filament branches (arrows). Bars ⫽ 10 m (a to c⬙).
Magnification, ⫻72,750 (d to f).
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trol cells was distributed as clustered small puncta near the
nucleus and plasma membrane, some cortactin antibody-injected cells (20 to 30%) displayed a substantial, but not complete, decrease in staining intensity at both locations (data not
shown). Thus, we elected to digitally quantify the mean fluorescence intensity per unit area of internalized transferrin in
these inhibited cells. While microinjection of buffer alone or
kinesin antibody did not result in decreased transferrin intensity, the cortactin antibody-injected cells that showed partial
inhibition were on average only 40% as intense as control,
noninjected cells (Fig. 4f). Consistent with the transferrin internalization experiments, the RME of LDL was also affected.
Microinjection of the same cortactin antibodies resulted in a
block of LDL internalization in the majority of cells (Fig. 5a,
a⬘, and c). Upon quantitation of the mean fluorescence intensity of LDL in these cells, there was a 40 to 50% decrease in
internalization compared to control (Fig. 5d). These results,
together with the cells that appeared to be completely blocked
in each condition, indicated that the cortactin antibodies potently inhibited the internalization of transferrin and LDL. In
contrast, cortactin antibody-injected cells showed no reduction
in the ability to internalize fluid markers, such as fluorescent
dextran (Fig. 6).
In an attempt to further define how cortactin may mediate
RME, we transiently expressed the cortactin SH3 domain in
cells. We rationalized that the expressed SH3 domain could
competitively inhibit RME by interfering with the normal function of cortactin and interactions with its binding partners, such
as dynamin. Mainly, expression of the SH3 domain produced
cell phenotypes strikingly similar to those observed in the antibody microinjection experiments and significantly reduced
the uptake of transferrin (Fig. 4d, e, and g), and LDL (Fig. 5b,

b⬘, e, and f). Importantly, expression of full-length cortactin in
these same experiments had no significant effects on RME
(Fig. 4e and g and 5e and f). These results suggested that the
SH3 domain of cortactin has an important role in linking
cortactin and/or dynamin to the functional endocytic complex.
DISCUSSION
In this study we demonstrate a structural and functional
association between the actin-binding protein cortactin and
CCPs in cultured epithelial cells. This study was initiated based
on previously published data that the SH3 domain of cortactin
binds to the proline-rich tail of Dyn2 (19). While this earlier
study demonstrated a convincing codistribution of these proteins in peripheral membrane ruffles, it was unclear if an association occurred at the site of RME. Because dynamin functions during the endocytic process, it prompted us to test if
cortactin and Dyn2 interactions are required to support invagination of the plasma membrane and subsequent internalization of ligand. Several morphological techniques demonstrated
a convincing colocalization between cortactin, Dyn2, and clathrin. The methods used in this study included immunofluorescence cell staining with two polyclonal antibodies made to
distinct cortactin domains (Fig. 2), expression of RFP-tagged
cortactin protein (Fig. 2), and high-resolution immuno-gold
electron microscopy with the same antibodies (Fig. 2). All
three of these methods were supportive of each other and
consistently localized cortactin to CCPs. Interestingly, the electron micrographs showed that at initial steps of invagination,
cortactin localized throughout flat clathrin lattices. At later
stages, the cortactin was primarily located in a ring or collar
around the neck of the pit, with some occasionally remaining at
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FIG. 3. Inhibition of clathrin-mediated endocytosis in cells expressing GTPase-deficient Dyn2 results in an abnormal distribution of both
cortactin and clathrin. Clone 9 cells transiently expressing GTPase-deficient Dyn2K44A-GFP were fixed and labeled to visualize the clathrin (X-22
monoclonal antibody) and cortactin (C-Tyr). (a to a⬙) Cells expressing the Dyn2 mutant (asterisks) have numerous clustered and clumpy-looking
clathrin pits (a⬘ and b⬘, arrows) in comparison to neighboring nontransfected cells. The defective clathrin staining dramatically colocalized with
cortactin (a⬙ and b⬙, arrows). Bar ⫽ 10 m.
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the bulb of the invaginating pit. This is not unlike what we and
others have observed for dynamin (4, 33). Exactly why some of
the cortactin and Dyn2 remain associated with the bulb of the
pit is unclear, but perhaps part of this complex is a remnant of
the protein associated with the flat clathrin lattice prior to
curvature or is providing nucleation sites for actin filaments to
push the vesicle from the plasma membrane.
Consistent with the localization studies, the same antibody
reagents exhibited a potent inhibitory effect on cell function.
Both antibodies significantly inhibited RME of transferrin and
LDL but not the uptake of fluid markers (Fig. 4, 5, and 6). As
multiple laboratories have observed different requirements for
dynamin in fluid-phase internalization (6, 16, 22), it was unclear if cortactin would be required in this process or not. One
possibility is that cortactin’s role in fluid-phase endocytosis is
not during internalization but rather during postendocytic trafficking and movement via actin polymerization, as has been
observed for both cortactin and Dyn2 (14, 16, 22). It is likely
that cortactin is associated with actin microfilaments in close
proximity to the clathrin lattice (Fig. 2d to f). Actin microfilaments are thought to function during early stages of pit invagination and to organize pit assemblies that aid in nascent vesicle fission from the plasma membrane (26, 28). Cortactin’s
proposed function as a protein that enhances microfilament
nucleation via the Arp2/3 complex and stabilizes actin filaments and branches supports such a function for cortactin in

RME. Further, recent data demonstrating cortactin’s role together with Dyn2 in other actin-dependent membrane processes supports the hypothesis that cortactin and Dyn2 function together with actin to mediate vesicle formation. The
action of such a complex could be coordinated by integration
with a host of proteins. The Dyn2 polymer, along with cortactin, could form a complex meshwork comprised of multiple
actin-binding proteins including profilin (42), Abp1 (15), syndapin (25), N-WASp (35); structural coat proteins such as
amphiphysin (7), AP2 (38), and clathrin (34); and signaling
molecules including PIP2 (17, 45), phospholipase C-␥ (31), and
Src (1, 5). The cortactin SH3 domain expression experiments
demonstrate that the SH3 domain of cortactin is important for
RME. It is attractive to predict that cortactin’s SH3 domain is
binding to dynamin and other putative partners at the forming
vesicle. As the injection of cortactin antibodies or expression of
multiple truncated cortactin constructs did not inhibit the recruitment of Dyn2 to clathrin pits, it is likely that cortactin does
not directly recruit Dyn2 to the pit. As there are multiple
Dyn2-binding partners at the endocytic site (endophilin, intersectin, amphiphysin, Grb2, and AP2) (18), it is likely that the
Dyn2-cortactin binding contributes to membrane deformation
and actin assembly rather than direct recruitment.
Finally, dynamin is known to interact with other actin-associated proteins, including syndapin (27), profilin (42), and
Abp1 (15). Abp1 was shown to regulate RME through actin
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FIG. 4. Cortactin antibody injection and expression of the SH3 domain significantly inhibit RME of transferrin. (a) Transferrin fluorescence
images of cultured cells microinjected (asterisk) with purified antibodies or expressing the cortactin SH3 domain. All injectate solutions contained
FITC-dextran to confirm successful injections. Injection of kinesin antibody had no effect on the internalization of Alexa 594-transferrin. (b and
c) In contrast, cells microinjected with either the AB3 or C-Tyr purified cortactin antibodies showed significant inhibition of the RME of Alexa
594-transferrin. (d) Expression of the SH3 domain also potently blocked transferrin internalization, demonstrating the importance of cortactin’s
SH3 domain for RME. Bar ⫽ 10 m. (e) The antibody-injected and SH3 domain-expressing cells showing a block in endocytosis were counted.
Whereas the number of cells with normal uptake is not affected in buffer and kinesin antibody-injected cells, only ⬃20% of cells injected with
cortactin antibody or expressing the SH3 domain had normal uptake. (f and g) Fluorescence intensity (FI) quantitation of internalized transferrin
confirmed that, when compared to controls, there is a significant 60% block in the antibody-injected cells (f) and a 70% block in the cells expressing
the SH3 domain (g). Cort wt ⫽ full-length cortactin, SH3 ⫽ cortactin SH3 domain.
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FIG. 5. Cortactin function is also required for the RME of LDL. (a
and a⬘) A cortactin AB3 antibody-injected cell (asterisk) demonstrating a significant block in the level of internalized DiI-LDL compared
to neighboring noninjected cells. (b and b⬘) Cells expressing the cortactin SH3 domain (asterisk) also demonstrated substantially reduced
internalization of LDL compared to neighboring, nonexpressing cells.
(c and d) Quantitation of the effect of cortactin antibody injection on
LDL internalization. Nearly 80% of the cells injected with cortactin
antibodies appeared blocked. Fluorescence intensity (FI) quantitation
of internalized LDL in these antibody-injected cells showed only 40 to
50% uptake compared to buffer-injected, kinesin antibody-injected, or
noninjected neighbors. (e and f) Quantitation of the effect of cortactin
SH3 domain expression on LDL internalization. Over 80% of the cells
expressing the SH3 domain appeared blocked (e). Fluorescence intensity quantitation of internalized LDL in these SH3 domain-expressing
cells showed only 40 to 50% uptake compared to neighboring nontransfected cells (f). Bar ⫽ 10 m. Cort wt, full-length cortactin; SH3,
cortactin SH3 domain.

and dynamin (15). Significantly, mammalian Abp1, unlike cortactin, lacks the acidic amino acid residues that mediate direct
binding to the Arp2/3 complex (28). This is an important distinction that increases the inherent importance of the cortactin-Dyn2 interaction. Actin nucleation has been suggested to
be important for RME, and the fact that cortactin stimulates
actin nucleation and that this activity is affected by binding to
dynamin (30) suggests that cortactin may serve a more direct
role during RME, rather than functioning as a scaffolding
molecule that links actin filaments and Dyn2. Interestingly,
when cortactin’s binding domain is removed from Dyn2
(Dyn2⌬PRD), there are alterations in associated actin organization, Dyn2 no longer localizes to CCPs and RME is inhibited
(19, 22, 32). Based on this study, and others, an attractive
model predicts that the SH3 domain of cortactin binds to the
PRD of Dyn2 at the invaginating CCP. The direct interaction
of these two proteins integrates dynamic actin filaments and
the membrane fission machinery, possibly in a Src-sensitive
manner. Thus, the actin filament-binding and nucleation activity of cortactin and the membrane-modeling activity of Dyn2
may function together during RME to mediate the final scission step of endocytosis. A simplified model depicting cortactin
and dynamin and how they may integrate endocytic proteins at
the invaginating pit is shown in Fig. 7. Future studies further
defining how cortactin and Dyn2 mediate membrane invagina-
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FIG. 6. Inhibition of cortactin does not significantly affect fluidphase endocytosis. (a and a⬘) Cortactin antibody (AB3)-injected cells
(FITC-dextran) (asterisks) showed no obvious defect in the internalization of rhodamine-labeled dextran compared to their noninjected
neighbors. (b) The number of cells with normal uptake was unaffected
in cortactin antibody-injected cells, as reflected by the same number of
dextran-positive cells compared to buffer- and kinesin antibody-injected cells. (c) In agreement with the immunocytochemistry experiments, quantitation of the mean dextran fluorescence intensity (FI)
per unit area in cortactin antibody-injected cells revealed no significant
difference in dextran uptake compared to control conditions. The
results in this figure suggest that the reagents used in this study specifically affect cortactin function during RME and not during fluidphase endocytosis. Bar ⫽ 10 m.
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tion will provide important insights into the regulation of the
endocytic process.
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FIG. 7. Dynamin and cortactin as key components of the cytoskeletal-endocytic machinery. Dynamin interacts with numerous proteins that
function to regulate clathrin-dependent endocytosis. Oligomers of dynamin function to restrict or pinch the neck of the invaginating membrane
while multiple extended PRDs interact directly with a variety of other proteins, including cortactin, that serve to link Dyn2 to the actin cytoskeleton
and the Arp2/3 complex. The complex cytoskeletal network also includes interactions with other actin-binding proteins such as syndapin, N-WASp,
Abp1, and Hip1R (some not shown for simplification).
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